Background: The analgesic effect of xylocaine alone versus xylocaine with corticosteroid injection after ultrasonographically (US)-guided treatment of rotator cuff calcific tendonosis has not been described in English literature. The aim of this study was to compare the analgesic effect of xylocaine only with xylocaine and corticosteroid following US-guided percutaneous treatment of rotator cuff calcific tendonosis. Methods: This prospective study enrolled 88 patients who were given different analgesic treatments [xylocaine only, n ¼ 23; xylocaine with corticosteroid, n ¼ 44; control (no xylocaine or corticosteroid), n ¼ 21]. The assessment of a patient's painful symptoms was recorded before treatment, and 1 day, 1 week, 1 month and 3 months after treatment using the visual analogue scale (VAS). Results: There were no significant differences in age, sex, calcification size before and after treatment, and amount of calcification decrease after treatment, but there was a significant difference in calcification morphology among the groups ( p ¼ 0.010). General linear model analysis indicated that the three groups had no difference in pain prior to treatment. After treatment, the xylocaine only and the xylocaine with corticosteroid groups had less pain than the control group at 1 day, 1 week, and 1 month after treatment. At 3 months after treatment, the xylocaine only group had less pain than the control group ( p ¼ 0.039), and the xylocaine with corticosteroid and control groups had similar levels of pain. Conclusion: Injection of xylocaine alone after US-guided treatment of rotator cuff calcific tendonosis provided a longer pain relief period than that of a mixture of xylocaine with corticosteroid.
Introduction
Calcific tendonosis of the rotator cuff is a common disorder, especially in the supraspinatus tendon, 1 and usually causes inflammation and pain in the shoulder region. The pathogenesis of rotator cuff calcification is uncertain, but it may be due to ischemia 2 or degeneration 3 leading to fibrocartilaginous metaplasia and ultimately calcification. 4, 5 Previous research reported that chronic and acute calcific tendonosis were mostly caused by the deposition of hydroxyapatite (HAP) in the periarticular tendon. 6 Diverse methods can be used to manage rotator cuff calcific tendonosis. Conservative treatments include physical therapy with a short course of an oral nonsteroidal antiinflammatory Conflicts of interest: The authors declare that there are no conflicts of interest related to the subject matter or materials discussed in this article.drug (NSAID), 1 lithotripsy by arthroscopy, 7, 8 an image-guided fluoroscopic procedure, 9, 10 extracorporeal shock wave therapy, 1e12 or single or two-needle ultrasonographically (US)-guided techniques. 13e19 Although there is no proven advantage of single or two-needle US-guided techniques, there is potential for tendon damage from use of multiple needles or a large needle. Previous studies indicated that US-guided fineneedle repeated puncture was an effective method for treatment of rotator cuff calcific tendonosis. 17, 19 Although the US-guided technique is effective for management of calcific tendonosis, most patients complain of severe pain for 1 week or more after this procedure. Fortunately, this pain can often be resolved by use of analgesic drugs and corticosteroid injection into the subdeltoid bursa.
13e19 Nevertheless, the analgesic effect of xylocaine alone versus xylocaine and corticosteroid injection has not been described in English literature. The US-guided fine-needle repeated puncture treatment creates an iatrogenic inflammatory process, which is necessary for effective resorption of calcium HAP following treatment of calcific tendonosis. The additional corticosteroid could potentially compromise the inflammatory process.
The purpose of this study is to compare the analgesic effect of xylocaine alone with xylocaine and corticosteroid injection of the subdeltoid bursa after a US-guided procedure for management of calcific tendonosis.
Methods

Participants
This was a prospective study that enrolled consecutive outpatients at the department of orthopedics or patients in rehabilitation due to chronic shoulder pain for >6 months. The primary inclusion criterion was the presence of calcifications within the rotator cuff with confirmation by gray-scale US. All patients who had previous invasive treatment for calcifications within the rotator cuff, including lithotripsy, arthroscopy or other imaging-guided procedures, and extracorporeal shock wave therapy were excluded. In addition, patients who had corticosteroid injections in the previous 6 months or concomitant rotator cuff tear were excluded. A total of 88 participants (29 men and 59 women; mean age: 57.9 years; age range: 32e83 years) who received US-guided repeated puncture for calcifications were enrolled from October 2009 to December 2011. All participants provided written informed consent for US-guided treatment of rotator cuff calcific tendonosis. Investigative and interventional procedures were performed according to the guidelines of the Helsinki Declaration and were approved by an institutional review board in Taipei Veterans General Hospital.
Pain assessment
The clinical assessment employed a visual analogue scale (VAS), in which each patient graded his/her own symptoms from 0 (painless) to 10 (the most painful sensation). Pain assessment was performed before treatment, and 1 day, 1 week, 1 month and 3 months after treatment by telephone query from a clinical assistant who was blinded to the treatments of all patients.
US-guided technique for treatment of rotator cuff calcific tendonosis
The morphology of the calcification, based on highresolution US (HRUS), was classified as an arc, fragmented, nodular, or cystic 16, 17 and the longest diameter of the calcification was recorded. Prior to use of the US-guided technique, each patient was given the opportunity to receive treatment with xylocaine alone, or treatment with xylocaine and corticosteroid, or no analgesic drug (control group). Patients in the xylocaine group were given 2 mL of 2% xylocaine (Recipharm Monts, Monts, France) and patients in the xylocaine with corticosteroid group were given 1 mL of 2% xylocaine mixed with 1 mL of corticosteroid (10 mg triamcinolone acetonide, Shincort, Yung Shin Pharmaceutical Industrial Company, Taichung, Taiwan). All injections were into the subdeltoid bursa with US guidance. If a patient did not want to choose or did not know how to choose a treatment group, a coin toss was used to determine group assignment.
The puncture procedure was performed with a USmonitored free-hand method. The needle tip was placed in the calcification, which was then punctured by moving the needle back and forth. There was no large-needle lavage in this study. The puncture needle was a 3.8 cm 21 gauge needle attached on a 10 mL syringe. Prior to the procedure, the skin of the puncture site was sterilized with beta iodine, and the transducer was covered with a sterilized plastic bag. Less than 2 mL of 2% xylocaine was injected in the subcutaneous and muscle layer. The US-guided repeated punctures were performed by moving the needle back-and-forth 20e40 times, according to the size and other characteristics of the calcifications, without removing the needle from the initial puncture site. The needle tract was monitored by HRUS to ensure that it had penetrated the calcification. After this procedure, analgesia (xylocaine or xylocaine with corticosteroid) was injected into the subdeltoid bursa. The puncture site was bandaged with self-administered hand compression for 15 minutes. All patients were sent home and encouraged to actively exercise the affected shoulder starting the next day. 16, 17 All US examinations and US-guided treatments were performed by one of the authors (H.J.C.) who has >20 years of experience in US and 15 years of experience in musculoskeletal US.
Each participant's symptoms were recorded before treatment, and 1 day, 1 week, 1 month and 3 months after treatment by telephone query from a clinical assistant who was blinded to the treatment. All patients also returned for follow-up US examinations by the same author (H.J.C.) at 6 months after treatment.
The US machines were the GE Voluson E8 system (GE Medical Systems, Milwaukee, WI, USA) with the SP 10-16-D linear transducer, the Philips iU 22 system (Philips-ATL, Bothell, WA, USA) with the L12-5 linear transducer, and the Siemens S2000 system (Siemens, Mountain View, CA, USA) with the 14L5 linear transducer.
Statistical analysis
The Chi-square test or Fisher's exact test was used to assess differences in sex and type of calcification, and a one-way analysis of variance was used to assess differences in patient age, calcification size, and VAS scores at different times. A general linear model was used to assess differences in pre-and posttreatment VAS values. A p value <0.05 was considered significant and all statistical analyses were performed with SPSS version 17 for Windows (SPSS Inc., Chicago, IL, USA).
Results
A total of 23 patients received 2 mL of xylocaine only, 44 patients received 1 mL of xylocaine mixed with 1 mL of corticosteroid, and 21 patients received no analgesic. There were no significant differences among these groups in age ( p ¼ 0.696), sex ( p ¼ 0.698), calcification size before treatment ( p ¼ 0.245), calcification size after treatment ( p ¼ 0.970), and change in calcification size ( p ¼ 0.900) ( Table 1) . However, there was a significant difference in calcific morphology among the three groups ( p ¼ 0.020). Arc type of calcification was most common in the control group, nodular type of calcification was most common in the xylocaine only group, and arc type of calcification was most common in the xylocaine with corticosteroid group.
In the xylocaine-only group, the mean VAS pain declined from 6.35 to 0.65 at 3 months after treatment, and the mean size of the calcification declined from 1.00 cm to 0.3 cm at 6 months after treatment. Fig. 1 shows a representative patient from this group. In the xylocaine with corticosteroid group, the mean VAS pain declined from 6.18 to 1.98 at 3 months after treatment and the mean size of the calcification declined from 0.92 cm to 0.28 cm at 6 months after treatment. Fig. 2 shows a representative patient from this group. In the control group, the mean VAS pain declined from 5.14 to 1.81 at 3 months after treatment and the mean size of the calcification declined from 1.02 cm to 0.29 cm at 6 months after treatment. Among the three groups, there was no significant difference in VAS pain before treatment ( p ¼ 0.194), but the VAS pain 1 day ( p < 0.001), 1 week ( p < 0.001), 1 month ( p ¼ 0.017) and 3 months ( p ¼ 0.019) after treatment was significantly lower in the xylocaine-only group and in the xylocaine with corticosteroid group relative to the control group ( Table 1) . None of the patients experienced complications, such as bleeding, infection, or ligament tear.
Finally, we used general linear model analysis to compare the levels of VAS pain in the three groups at different times after treatment. The results indicate no significant difference in pain before treatment, but significantly less pain in the xylocaine-only and the xylocaine with corticosteroid groups relative to the control group at 1 day, 1 week, and 1 month after treatment (Table 2) . At 3 months after treatment, VAS pain in the xylocaine only group was significantly less than that in the control group ( p ¼ 0.039), but VAS pain in the xylocaine with corticosteroid group was not significantly different from that in the control group ( p ¼ 0.730). The same results were found after controlling for type of calcification (data not shown).
Discussion
The US-guided procedure used to treat calcific tendonosis introduces iatrogenic minor trauma over the calcification, which results in acute inflammation, neovascularization, and increased macrophages that remove the calcium. 17 Although the US-guided technique is effective for management of calcific tendonosis, 13e18 most patients complain of severe pain for >1 week after the procedure. Fortunately, this pain can be managed by use of analgesic drugs or corticosteroid injections into the subdeltoid bursa. In this study, we found that the percent decrease in calcifications after surgery was similar for patients in the xylocaine, xylocaine with corticosteroid, and control groups. Thus, these analgesics appeared to have no effect on the resorption of calcifications. However, patients in the xylocaine only group had less pain at 3 months after surgery than those in the xylocaine with corticosteroid group and in the control group.
Corticosteroid injection can relieve the shoulder pain associated with diverse musculoskeletal conditions. 20e26 These drugs have antiinflammatory effects, inhibit the synthesis of glycosaminoglycans, proteins, and collagen, 27 and alter fibroblast proliferation and metabolism. 28 However, these later effects may be classified as antianabolic, so corticosteroids may also have adverse effects on wound and soft tissue healing. 29, 30 Thus, the short term use of an analgesic such as xylocaine is often recommended for relief of shoulder pain in order to prevent the adverse effects of corticosteroids in soft tissue. 21,23e26 Xylocaine is generally used as a local analgesic and is injected into subcutaneous, intramuscular, or intrabursal regions. Although xylocaine is also associated with some adverse cardiovascular and neurological effects, these typically only occur following large doses or intravascular injections.
Xylocaine only provides short-term relief from pain, so it may be combined with a corticosteroid in order to provide prolonged pain relief. In particular, xylocaine provides shortterm pain relief due to its effect as a local anesthetic (inhibition of neuronal ion fluxes), but corticosteroids provide longterm relief from pain due to their long-term effects on diverse types of cells and endogenous molecules involved in inflammation. 31, 32 The US-guided fine-needle repeated puncture treatment creates an iatrogenic inflammatory process, which is necessary for effective resorption of calcium HAP following treatment of calcific tendonosis. Our results indicate that the xylocaine only and the xylocaine with corticosteroid groups had similarly reduced levels of pain relative to the control group for up to 1 month after US-guided treatment for calcific tendonosis. However, the xylocaine only group had less pain than the xylocaine with corticosteroid group at 3 months after treatment. Corticosteroid injections are believed to compromise the inflammatory process and inhibit the resorption of calcifications following percutaneous treatment of rotator cuff calcific tendonosis.
Our study had several limitations. First, participants were not randomized and this could have led to selection bias. Second, all patients were treated by US-guided repeated punctures, and single or double lavage techniques, which are common in some institutions, were not performed. Third, the follow-up time was only 3 months for assessment of pain, but was 6 months for assessment of calcific morphology. It would have been better to perform a final pain assessment at 6 months. In our institute, US-guided treatment of rotator cuff tendonosis is routinely performed 6 months after treatment. Fourth, we only examined the effect of a single corticosteroid dose of 10 mg. However, our results showed a clear difference between the xylocaine only and the xylocaine with corticosteroid groups compared to the control group from 1 day to 1 month after surgery.
In conclusion, patients who received US-guided percutaneous treatment for rotator cuff calcific tendonosis and were given a xylocaine injection experienced less pain at 3 months than those given a xylocaine and corticosteroid injection. Injection of xylocaine alone appears to provide effective relief from the shoulder pain associated with US-guided repeated punctures for treatment of rotator cuff calcific tendonosis. . Six months later, ultrasonography showed a cluster of punctate calcification spots, with >50% reduction in calcification (arrowheads in C), and the patient reported marked reduction of pain.
